| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
62,894,000 |
| Market
Cap: |
2.43(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.61 - $51.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies. Co.'s clinical development programs include: CDX-0159, which is a human monoclonal antibody that specifically binds the receptor tyrosine kinase KIT; CDX-1140, which is a human monoclonal antibody targeted to CD40, a key activator of immune response, which is being studied in a Phase1 study; and CDX-527, which is a bispecific antibody that uses Co.'s proprietary anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which Co. has initiated a Phase 1 study in advanced solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
223,855 |
| Total Sell Value |
$0 |
$0 |
$0 |
$8,358,941 |
| Total People Sold |
0 |
0 |
0 |
6 |
| Total Sell Transactions |
0 |
0 |
0 |
8 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jimenez Freddy A. |
SVP & GENERAL COUNSEL |
• – – |
2024-02-13 |
4 |
OE |
$2.78 |
$93,163 |
D/D |
24,166 |
25,924 |
|
- |
|
| Martin Samuel Bates |
SVP AND CFO |
• – – |
2024-01-02 |
4 |
OE |
$2.78 |
$29,885 |
D/D |
10,750 |
35,128 |
|
- |
|
| Keler Tibor |
EXECUTIVE VP & CSO |
• – – |
2022-12-07 |
4 |
S |
$36.93 |
$622,611 |
D/D |
(16,860) |
7,357 |
|
2% |
|
| Keler Tibor |
EXECUTIVE VP & CSO |
• – – |
2022-12-07 |
4 |
OE |
$2.78 |
$46,871 |
D/D |
16,860 |
24,217 |
|
- |
|
| Cavanaugh Sarah |
SVP OF CORP AFFAIRS & ADMIN. |
• – – |
2022-08-18 |
4 |
S |
$36.38 |
$49,289 |
D/D |
(1,355) |
1,284 |
|
-32% |
|
| Cavanaugh Sarah |
SVP OF CORP AFFAIRS & ADMIN. |
• – – |
2022-08-18 |
4 |
OE |
$9.02 |
$12,217 |
D/D |
1,355 |
2,639 |
|
- |
|
| Cavanaugh Sarah |
SVP OF CORP AFFAIRS & ADMIN. |
• – – |
2022-08-17 |
4 |
S |
$36.73 |
$1,150,221 |
D/D |
(31,312) |
1,284 |
|
-32% |
|
| Cavanaugh Sarah |
SVP OF CORP AFFAIRS & ADMIN. |
• – – |
2022-08-17 |
4 |
OE |
$2.78 |
$87,047 |
D/D |
31,312 |
32,596 |
|
- |
|
| Young Diane C. |
SVP, CHIEF MEDICAL OFFICER |
• – – |
2022-08-17 |
4 |
OE |
$2.71 |
$319,170 |
D/D |
64,000 |
47,115 |
|
- |
|
| Young Diane C. |
SVP, CHIEF MEDICAL OFFICER |
• – – |
2022-08-17 |
4 |
S |
$37.30 |
$708,715 |
D/D |
(19,000) |
2,115 |
|
-32% |
|
| Marucci Anthony S |
PRESIDENT & CEO |
• • – |
2022-08-15 |
4 |
S |
$37.66 |
$4,519,572 |
D/D |
(120,000) |
27,692 |
|
-16% |
|
| Marucci Anthony S |
PRESIDENT & CEO |
• • – |
2022-08-15 |
4 |
OE |
$2.78 |
$614,243 |
D/D |
120,000 |
147,692 |
|
- |
|
| Wright Richard M. |
SR. VP & CCO |
• – – |
2022-08-15 |
4 |
S |
$37.71 |
$578,048 |
D/D |
(15,328) |
208 |
|
-16% |
|
| Wright Richard M. |
SR. VP & CCO |
• – – |
2022-08-15 |
4 |
OE |
$10.38 |
$159,105 |
D/D |
15,328 |
15,536 |
|
- |
|
| Martin Samuel Bates |
SVP AND CFO |
• – – |
2022-08-12 |
4 |
S |
$34.62 |
$639,629 |
D/D |
(17,547) |
24,378 |
|
-18% |
|
| Martin Samuel Bates |
SVP AND CFO |
• – – |
2022-08-12 |
4 |
OE |
$2.78 |
$72,953 |
D/D |
17,547 |
41,925 |
|
- |
|
| Martin Samuel Bates |
SVP AND CFO |
• – – |
2022-08-11 |
4 |
S |
$37.04 |
$90,856 |
D/D |
(2,453) |
24,378 |
|
-31% |
|
| Martin Samuel Bates |
SVP AND CFO |
• – – |
2022-08-11 |
4 |
OE |
$9.02 |
$22,117 |
D/D |
2,453 |
26,831 |
|
- |
|
| Martin Samuel Bates |
SVP and CFO |
• – – |
2021-12-23 |
4 |
AS |
$42.00 |
$399,000 |
D/D |
(9,500) |
24,378 |
|
-24% |
|
| Martin Samuel Bates |
SVP and CFO |
• – – |
2021-12-23 |
4 |
OE |
$2.78 |
$39,729 |
D/D |
7,000 |
33,878 |
|
- |
|
| Heath-Chiozzi Margo |
SVP of Regulatory Affairs |
• – – |
2021-12-08 |
4 |
AS |
$40.00 |
$24,000 |
D/D |
(600) |
11,247 |
|
-13% |
|
| Heath-Chiozzi Margo |
SVP of Regulatory Affairs |
• – – |
2021-12-08 |
4 |
OE |
$2.78 |
$1,668 |
D/D |
600 |
11,847 |
|
- |
|
| Cavanaugh Sarah |
SVP of Corp Affairs & Admin. |
• – – |
2021-12-08 |
4 |
AS |
$40.00 |
$292,920 |
D/D |
(7,323) |
408 |
|
-13% |
|
| Cavanaugh Sarah |
SVP of Corp Affairs & Admin. |
• – – |
2021-12-08 |
4 |
OE |
$9.02 |
$73,481 |
D/D |
7,323 |
7,731 |
|
- |
|
| Crowley Elizabeth |
Sr. VP &CPDO |
• – – |
2021-12-08 |
4 |
AS |
$40.00 |
$160,000 |
D/D |
(4,000) |
4,726 |
|
-13% |
|
121 Records found
|
|
Page 1 of 5 |
|
|
0.47 (1.2%) 
